S. Fadilah Abdul Wahid

S. Fadilah Abdul Wahid

Auto-generated profile, based on publicly available information

S. Fadilah Abdul Wahid

Cell Therapy Center, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Kuala Lumpur, Malaysia, 56000

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Stem Cells and Development
Verified
Journal Article
Closed access
SWS. Fadilah Abdul Wahid
S. Fadilah Abdul Wahid
NINor-Azimah Ismail
Nor-Azimah Ismail
MMMohd-Razif Mohd-Idris
Mohd-Razif Mohd-Idris
FJFariza Wan Jamaluddin
Fariza Wan Jamaluddin
NTNor Rafeah Tumian
Nor Rafeah Tumian
MNMing Lai Nai
Ming Lai Nai
Currently, the indications to perform reduced-intensity conditioning allogeneic hematopoietic stem cell transplant (RIC-HCT) are based on data derived mainly from large registry and single-centre retrospective studies. Thus, at the present time, there is limited direct evidence supporting the current practice in selecting patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) for RIC versus myeloablative conditioning (MAC) transplants. To determine the relationship between dose intensity of conditioning regimen and survival outcomes after allografting in AML/ALL patients, we performed a meta-analysis of 23 clinical trials reported between 1990 and 2013 involving 15,258 adult patients that compare survival outcomes after RIC-HCT versus MAC-HCT. RIC-HCT resulted in comparable <2-year and 2-6 year overall survival (OS) rates post-transplantation even though the RIC-HCT recipients were older and had more active disease than MAC-HCT recipients. The 2-6 year progression-free survival (PFS), nonrelapse mortality, acute graft-versus-host disease (GvHD) and chronic GvHD rates were reduced after RIC-HCT, but relapse rate was increased. Similar outcomes were observed regardless of disease type and status at transplantation. Odds ratio for all outcomes remained comparable with or without performing separate analyses for the year of HCT and for retrospective versus prospective studies. Among RIC-HCT recipients, survival rates were superior if patients were in CR at transplantation. Significant inter-study heterogeneity for aGvHD data and publication bias for PFS data were observed. This meta-analysis showed no OS benefit of MAC-HCT over RIC-HCT across the entire cohort of patients suggesting that RIC-HCT could be an effective therapeutic option for AML/ALL patients who are ineligible for MAC-HCT and CR status is preferred before RIC-HCT.

1 August 2015 in Journal of Clinical Virology
Verified
Journal Article
Closed access
WJWAN FARIZA WAN JAMALUDIN
WAN FARIZA WAN JAMALUDIN
PPPetrick Periyasamy
Petrick Periyasamy
WMWan Rahiza Wan Mat
Wan Rahiza Wan Mat
SWS. Fadilah Abdul Wahid
S. Fadilah Abdul Wahid

9 April 2018 in Current Stem Cell Research & Therapy
Verified
Journal Article
Closed access
PDF file
FWFadilah S. Abdul Wahid
Fadilah S. Abdul Wahid
NINor Azimah Ismail
Nor Azimah Ismail
WJWan Fariza Wan Jamaluddin
Wan Fariza Wan Jamaluddin
NMNor Asiah Muhamad
Nor Asiah Muhamad
MIMohamad Mohamad Azim Mohamad Idris
Mohamad Mohamad Azim Mohamad Idris
NLNai Ming Lai
Nai Ming Lai
Background: Revascularisation therapy is the curent gold standard of care for critical limb ischaemia (CLI), although a significant proportion of patients with CLI either are not fit for or do not respond well to this procedure. Recently, novel angiogeneic therapies such as the use of autologous cell-based therapy (CBT) have been examined, but the results of individual trials were inconsistent. Objective:To pool all published studies that compared the safety and efficacy of autologous CBT derived from different sources and phenotypes with non cell-based therapy (NCT) in CLI patients. Methods: We searched Medline, Embase, Cochrane Library and ClinicalTrials.gov from 1974-2017. Sixteen randomised clinical trials (RCTs) involving 775 patients receiving the following interventions: mobilised peripheral blood stem cells(m-PBSC), bone marrow mononuclear cells(BM-MNC), bone marrow mesenchymal stem cells(BM-MSC), cultured BM-MNC(Ixmyelocel-T), cultured PB cells(VesCell) and CD34+ cells were included in the meta-analysis. Results: High-quality evidence (QoE) showed similar all-cause mortality rates between CBT and NCT. AR reduction by approximately 60% were observed in patients receiving CBT compared to NCT (moderate QoE). CBT patients experienced improvement in ulcer healing, ABI, TcO2, pain free walking capacity and collateral vessel formation (moderate QoE). Low-to-moderate QoE showed that compared to NCT, intramuscular BM-MNC and m-PBSC may reduce amputation rate, rest pain, and improve ulcer healing and ankle-brachial pressure index, while intramuscular BM-MSC appeared to improve rest pain, ulcer healing and pain-free walking distance but not AR. Efficacy of other types of CBT could not be confirmed due to limited data. Cell harvesting and implantation appeared safe and well-tolerated with similar rates of adverse-events between groups. Conclusion: Implantation of autologous CBT may be an effective therapeutic strategy for no-option CLI patients. BM-MNC and m-PSBC appear more effective than NCT in improving AR and other limb perfusion parameters. BM-MSC may be beneficial in improving perfusion parameters but not AR, however this observation need to be confirmed in a larger population of patients. Generally, treatment using various sources and phenotypes of cell products appeared safe and well tolerated. Large-size RCTs with long follow-up are warranted to determine the superiority and durability of angiogeneic potential of a particular CBT and the optimal treatment regimen for CLI.

29 August 2018 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
SWS Fadilah Abdul Wahid
S Fadilah Abdul Wahid
NINor Azimah Ismail
Nor Azimah Ismail
WJWan Fariza Wan Jamaludin
Wan Fariza Wan Jamaludin
NMNor Asiah Muhamad
Nor Asiah Muhamad
MHMuhammad Khairul Azaham Abdul Hamid
Muhammad Khairul Azaham Abdul Hamid
NLNai Ming Lai
Nai Ming Lai


19 December 2019 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
SWS Fadilah Abdul Wahid
S Fadilah Abdul Wahid
ZLZhe Kang Law
Zhe Kang Law
NINor Azimah Ismail
Nor Azimah Ismail
NLNai Ming Lai
Nai Ming Lai